|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAPKAPK5 |
Gene summary for MAPKAPK5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAPKAPK5 | Gene ID | 8550 |
| Gene name | MAPK activated protein kinase 5 | |
| Gene Alias | MAPKAP-K5 | |
| Cytomap | 12q24.12-q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q8IW41 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8550 | MAPKAPK5 | P130T-E | Human | Esophagus | ESCC | 3.65e-45 | 8.68e-01 | 0.1676 |
| 8550 | MAPKAPK5 | HCC1_Meng | Human | Liver | HCC | 6.49e-47 | 3.55e-02 | 0.0246 |
| 8550 | MAPKAPK5 | HCC2_Meng | Human | Liver | HCC | 9.90e-13 | 4.16e-02 | 0.0107 |
| 8550 | MAPKAPK5 | HCC2 | Human | Liver | HCC | 6.07e-04 | 2.84e+00 | 0.5341 |
| 8550 | MAPKAPK5 | S014 | Human | Liver | HCC | 1.26e-09 | 5.41e-01 | 0.2254 |
| 8550 | MAPKAPK5 | S015 | Human | Liver | HCC | 1.29e-10 | 7.18e-01 | 0.2375 |
| 8550 | MAPKAPK5 | S016 | Human | Liver | HCC | 1.47e-12 | 6.40e-01 | 0.2243 |
| 8550 | MAPKAPK5 | S027 | Human | Liver | HCC | 3.67e-04 | 6.98e-01 | 0.2446 |
| 8550 | MAPKAPK5 | S028 | Human | Liver | HCC | 4.05e-09 | 6.71e-01 | 0.2503 |
| 8550 | MAPKAPK5 | S029 | Human | Liver | HCC | 1.49e-08 | 6.37e-01 | 0.2581 |
| 8550 | MAPKAPK5 | C04 | Human | Oral cavity | OSCC | 9.76e-20 | 8.52e-01 | 0.2633 |
| 8550 | MAPKAPK5 | C21 | Human | Oral cavity | OSCC | 1.16e-36 | 8.73e-01 | 0.2678 |
| 8550 | MAPKAPK5 | C30 | Human | Oral cavity | OSCC | 1.43e-26 | 9.86e-01 | 0.3055 |
| 8550 | MAPKAPK5 | C38 | Human | Oral cavity | OSCC | 2.60e-04 | 6.93e-01 | 0.172 |
| 8550 | MAPKAPK5 | C43 | Human | Oral cavity | OSCC | 6.33e-18 | 4.18e-01 | 0.1704 |
| 8550 | MAPKAPK5 | C46 | Human | Oral cavity | OSCC | 9.16e-18 | 4.18e-01 | 0.1673 |
| 8550 | MAPKAPK5 | C51 | Human | Oral cavity | OSCC | 1.14e-09 | 4.53e-01 | 0.2674 |
| 8550 | MAPKAPK5 | C57 | Human | Oral cavity | OSCC | 3.03e-05 | 2.35e-01 | 0.1679 |
| 8550 | MAPKAPK5 | C06 | Human | Oral cavity | OSCC | 8.63e-05 | 7.25e-01 | 0.2699 |
| 8550 | MAPKAPK5 | C08 | Human | Oral cavity | OSCC | 1.31e-19 | 5.14e-01 | 0.1919 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:005105417 | Esophagus | ESCC | positive regulation of DNA metabolic process | 139/8552 | 201/18723 | 1.20e-11 | 4.33e-10 | 139 |
| GO:200057319 | Esophagus | ESCC | positive regulation of DNA biosynthetic process | 56/8552 | 66/18723 | 4.51e-11 | 1.45e-09 | 56 |
| GO:003220417 | Esophagus | ESCC | regulation of telomere maintenance | 65/8552 | 80/18723 | 6.02e-11 | 1.90e-09 | 65 |
| GO:2000278110 | Esophagus | ESCC | regulation of DNA biosynthetic process | 81/8552 | 106/18723 | 9.81e-11 | 2.96e-09 | 81 |
| GO:000700418 | Esophagus | ESCC | telomere maintenance via telomerase | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:200125219 | Esophagus | ESCC | positive regulation of chromosome organization | 64/8552 | 82/18723 | 1.98e-09 | 4.52e-08 | 64 |
| GO:1901796111 | Esophagus | ESCC | regulation of signal transduction by p53 class mediator | 70/8552 | 93/18723 | 5.69e-09 | 1.18e-07 | 70 |
| GO:001083319 | Esophagus | ESCC | telomere maintenance via telomere lengthening | 61/8552 | 81/18723 | 5.24e-08 | 9.37e-07 | 61 |
| GO:00322108 | Esophagus | ESCC | regulation of telomere maintenance via telomerase | 43/8552 | 53/18723 | 1.20e-07 | 1.95e-06 | 43 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:005197217 | Esophagus | ESCC | regulation of telomerase activity | 39/8552 | 47/18723 | 1.48e-07 | 2.35e-06 | 39 |
| GO:003220618 | Esophagus | ESCC | positive regulation of telomere maintenance | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
| GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:003221210 | Esophagus | ESCC | positive regulation of telomere maintenance via telomerase | 30/8552 | 34/18723 | 2.73e-07 | 4.02e-06 | 30 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAPKAPK5 | SNV | Missense_Mutation | novel | c.338G>T | p.Arg113Ile | p.R113I | Q8IW41 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| MAPKAPK5 | insertion | In_Frame_Ins | novel | c.271_272insTCTTTTTGAGAC | p.Glu91delinsValPheLeuArgGln | p.E91delinsVFLRQ | Q8IW41 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| MAPKAPK5 | SNV | Missense_Mutation | c.1300N>C | p.Asp434His | p.D434H | Q8IW41 | protein_coding | deleterious(0.02) | benign(0.264) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAPKAPK5 | SNV | Missense_Mutation | novel | c.544N>C | p.Thr182Pro | p.T182P | Q8IW41 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MAPKAPK5 | SNV | Missense_Mutation | rs745405567 | c.743N>A | p.Arg248Gln | p.R248Q | Q8IW41 | protein_coding | tolerated(0.4) | benign(0.051) | TCGA-A6-6649-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
| MAPKAPK5 | SNV | Missense_Mutation | novel | c.490N>T | p.Pro164Ser | p.P164S | Q8IW41 | protein_coding | tolerated(0.06) | possibly_damaging(0.549) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MAPKAPK5 | SNV | Missense_Mutation | novel | c.73A>C | p.Thr25Pro | p.T25P | Q8IW41 | protein_coding | tolerated(0.11) | possibly_damaging(0.581) | TCGA-AA-3814-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAPKAPK5 | SNV | Missense_Mutation | rs773408629 | c.23A>G | p.Asp8Gly | p.D8G | Q8IW41 | protein_coding | deleterious_low_confidence(0.03) | benign(0.025) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MAPKAPK5 | SNV | Missense_Mutation | novel | c.409C>T | p.Arg137Trp | p.R137W | Q8IW41 | protein_coding | deleterious(0.04) | benign(0.018) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
| MAPKAPK5 | SNV | Missense_Mutation | rs753238884 | c.1279N>T | p.Arg427Trp | p.R427W | Q8IW41 | protein_coding | deleterious(0.02) | possibly_damaging(0.646) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 363894142 | ||
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 249565858 | ||
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | GW843682X | GW843682X | ||
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL3545338 | GLPG-0259 | |
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | GLPG0259 | GLPG-0259 | ||
| 8550 | MAPKAPK5 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 249565857 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |